AGXX® - the new bioactive contact catalyst
for decontamination of aqueous systems

Practice Results - AGXX® in the Pharmaceutical & Medical Technology

Compared with aqueous processing solutions in the industry (in general), germs in medicine and the pharmaceutical industry carry far more serious consequences. Multi-drug resistant bacteria in hospitals are a serious problem with additional risks to patients and high economic costs.

Tests for the application of AGXX® in these areas have successfully started with AGXX® coatings in urologic applications, in eye drops and implants. The results from initial urological tests are briefly shown here as an example.

Straight native urine poses special challenges due to the high concentration of complex ingredients. The classic silver-containing products, therefore, fail in these applications, since silver ions are immediately inactivated by the high concentration of complexing agents. Furthermore, in many cases, antibiotics are no longer able to effectively destroy germs in the urine.

Comparison of Hemmhofbildung of Ag andAGXX® with septic urine samples Comparison of Hemmhofbildung of Ag and AGXX® with septic urine samples - a suspension culture with bacteria E. coli (RRI) made up in fresh urine is recognized (108/ml) with 25 µl in fresh urine and urine plated onto agar. Edition of AGXX® networks and incubation at 37 °C for 48 hours.

Our data show that in native urine when compared to pure water, a 1000-fold higher concentration of silver ions is necessary to kill an equally large amount of bacteria (105 CFU/ml) abzutöten.

In contrast, the antimicrobial action of AGXX® in urine is not sustainable blocked. Hemmhof tests show that AGXX® compared to a pure silver surface continues to have a high antimicrobial activity after inoculation with contaminated urine. .

In many pharmaceutical products the necessary classical preservatives cause adverse reactions. For example, for patients with increased eye pressure eye drops with chemical preservatives should be avoided. So multidose boxes which have to be kept germ-free with preservatives cannot be used.

That is why patients with glaucoma can only use disposable boxes for their eye drops. The value of the packaging considerably exceeds the value of the ingredient. Therefore, new solutions for multi-dose packaging without chemical preservatives will be searched.

Initial tests with AGXX® show that microbial strains in pharmaceutical solutions are efficiently eliminated. It is becoming apparent that AGXX® can meet all the demands that are placed on a preservative after drug approval.

 top   print   bookmark   recommend